SAFETY PROFILE OF NEXGARD
NexGard contains the active ingredient afoxolaner, which has been developed specifically for dogs. NexGard has been shown to be safe and effective in various breeds of dogs (including sensitive Collie breeds) when used as directed, and can be given to puppies from 8 weeks of age, providing they weigh at least 2 kg.

All medicines, including veterinary medicines, carry benefits and risks. Afoxolaner, the active ingredient in NexGard, is part of the isoxazoline family of chemicals. Adverse reactions to this family of chemicals are rarely observed but may include vomiting, diarrhoea, lethargy, inappetence (loss of appetite), itching and very rarely, seizures. Most adverse reactions are mild, self-limiting and of short duration. For dogs with a history of epilepsy or other seizure disorders, it is recommended to seek veterinary advice prior to treatment with medicines of this class.

Robust and extensive safety studies demonstrate NexGard’s excellent safety profile. This is further supported by our rigorous pharmacovigilance program which closely monitors and evaluates any suspected adverse events reported to the company by pet owners or veterinarians in all countries where the product is registered.

For more information please read the product information leaflet or if you have any questions about NEXGARD we encourage you to contact your Veterinarian or Boehringer Ingelheim Animal Health Customer Care directly on 1800 808 691.